Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 2/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.31 |
| ▸ | PARP11 | Q9NR21 | 2/20 | 0.31 |
| ▸ | CDC7 | O00311 | 1/20 | 0.31 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.31 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.31 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28840975 | 0.79 | CRBN (0.35) | CRBNPARP1PARP10PARP11PKN1 | |
| SCHEMBL28239984 | 0.76 | CCR6 (0.43) | CRBNCDC7 | |
| SCHEMBL24569857 | 0.75 | LMNA (0.37) | CRBN | |
| SCHEMBL24569436 | 0.75 | SLC6A2 (0.37) | CRBNPARP1 | |
| SCHEMBL240349 | 0.74 | — | — | |
| SCHEMBL685633 | 0.74 | — | — | |
| SCHEMBL29135187 | 0.71 | OR51E2 (0.39) | CRBN | |
| SCHEMBL7743558 | 0.71 | CRBN (0.35) | CRBNPARP1ACHEPARP10PARP11 | |
| SCHEMBL29135185 | 0.71 | OR51E2 (0.39) | CRBN | |
| SCHEMBL24569753 | 0.69 | CRBN (0.33) | CRBNPARP1PARP10PARP11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116921-A1 | LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN INC. | 2024-04-11 | — | — | US | disclosed |
| EP-4267137-A1 | LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 | Enliven Inc. (US) | 2023-11-01 | — | — | EP | disclosed |
| WO-2022140769-A1 | LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN THERAPEUTICS, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022140769-A1 | LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN THERAPEUTICS, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116921-A1 | LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 | ERBB2, FGFR2, ERBB3 | CRBN 1138/4885PARP1 1085/4885ACHE 3700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.